Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Textbook of Uncommon Cancer
Described as ‘must-have for cancer research’ by theHospital Doctor this highly acclaimed textbook has beenextensively revised and updated to reflect recent progress andunderstanding in the field. It is the only comprehensive source ofinformation available on uncommon cancers; presenting diagnosis,detailed clinical management and prognosis. The Textbook ofUncommon Cancer, Third Edition incorporated 18 newchapters, including: Tumors of the cervix Esthesioneuroblastoma Unusual malignancies of plasma cells Dermatofibrosarcoma protuberans Written by leading clinicians worldwide, this title isindispensable for all those involved in the diagnosis and treatmentof hard-to-manage rare tumors.
Big Pharma
To many Americans, the term big pharma evokes thoughts of greedy organizations that put profits ahead of people's health. It's difficult to put a price tag on drugs that improve or save lives. It's even harder to stomach the thought of being unable to afford medicines when we may need them most. With the price of pills reaching an all-time high, we are looking for justifications and turning to our government for solutions. The articles in this collection provide valuable coverage and insights into the practices of drug manufacturers, the driving forces behind the costs we face today, and what, if anything, can be done to satiate the hunger of big pharma. Media literacy questions and terms will engage readers beyond the text and aid them in considering the many facets of this complicated issue.
Research Activities
None
AACR 2019 Proceedings: Abstracts 2749-5314
American Association for Cancer Research 2019 Proceedings: Abstracts 2749-5314 - Part B
Contemporary Issues in Colorectal Cancer
Providing up-to-date management information for nurses educating the public on, and caring for patients with, colorectal cancer, these 15 contributions by US nursing specialists cover: epidemiology and risk; prevention and detection, including controversies over screening and the role of diet; patho
Developing and Sustaining an Effective and Resilient Oncology Careforce
The oncology careforce faces challenges as population growth in the U.S. contributes to increases in the number of patients diagnosed with cancer. Significant advances in cancer research, screening and diagnostic practices, and treatment have led to the age-adjusted declining mortality rate from cancer. However, as the field continues to develop and advance, cancer care has become more complex than ever before. There is a growing concern regarding the U.S. health care system's capacity to deliver high-quality cancer care to the increasing number of patients. The National Academies convened a workshop on February 11-12, 2019 to explore trends in cancer care and identify opportunities for improvement in the rapidly developing oncology careforce. Discussions at the workshop primarily focused on trends in demographics, the careforce, and oncology practice, as well as implications for the future of cancer care and strategies to improve the organization and delivery of cancer care. Opportunities to change policy and leverage technologies in oncology were also identified. This publication summarizes the presentations and discussions from the workshop.
A World Without Cancer
A provocative and surprising investigation into the ways that profit, personalities, and politics obstruct real progress in the war on cancer—and one doctor's passionate call to action for change This year, nearly 1.6 million new cases of cancer will be diagnosed and more than 1,500 people will die per day. We've been asked to accept the disappointing strategy to "manage cancer as a chronic disease." We've allowed pharmaceutical companies to position cancer drugs that extend life by just weeks and may cost $100,000 for a single course of treatment as breakthroughs. Why have we been able to cure and prevent other killer diseases but not most cancers? Where is the bold government leadership ...
Molecular Targeting in Oncology
This book presents an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer. It is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.
The Truth in Small Doses
A “brilliant” (Fortune), eye-opening history of the war on cancer, The Truth in Small Doses asks why we are losing this essential fight and charts a path forward. Over the past half century, deaths from heart disease, stroke, and so many other killers have fallen dramatically. But cancer continues to kill with abandon. In 2013, despite a four-decade “war” against the disease that has cost hundreds of billions of dollars, more than 1.6 million Americans will be diagnosed with cancer and nearly six hundred thousand will die from it. A decade ago, Clifton Leaf, a celebrated journalist and a cancer survivor himself, began to investigate why we had made such limited progress fighting this...
Improving Cancer Diagnosis and Care
A hallmark of high-quality cancer care is the delivery of the right treatment to the right patient at the right time. Precision oncology therapies, which target specific genetic changes in a patient's cancer, are changing the nature of cancer treatment by allowing clinicians to select therapies that are most likely to benefit individual patients. In current clinical practice, oncologists are increasingly formulating cancer treatment plans using results from complex laboratory and imaging tests that characterize the molecular underpinnings of an individual patient's cancer. These molecular fingerprints can be quite complex and heterogeneous, even within a single patient. To enable these molec...
